小分子LF3通过减轻心脏纤维化缓解血管新素II诱导的心脏功能障碍
Xiang Liu1, Chunyu Zhang1, Weiyi Jiang1
1Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Suzhou Medical College of Soochow University, 199 Ren-Ai Road, Suzhou, Jiangsu, 215123, China.
Naunyn-Schmiedeberg's archives of pharmacology
|March 9, 2026
概括
一种新型化合物LF3通过向Wnt/β-catenin通路,有效降低心脏纤维化并改善心脏功能. 这种有针对性的方法为心力衰竭进展提供了一个有希望的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 分子医学是分子医学.
背景情况:
- 心脏纤维化是心力衰竭进展的主要驱动因素.
- 目前的治疗方法缺乏直接针对心脏纤维化的药物.
- Wnt/β-catenin信号通路与纤维化有关,但上游抑制具有风险.
研究的目的:
- 评估LF3,β-catenin/TCF4相互作用抑制剂在缓解心脏纤维化的治疗潜力.
- 在心脏纤维化模型中研究LF3作用的潜在机制.
主要方法:
- 雄性小鼠接受了 ангиотензин II (Ang II) 输液以诱导心脏纤维化,并接受了 LF3.3 的治疗.
- 在体外研究中使用了与Ang II和LF3.3刺激的小鼠心脏纤维细胞.
- 评估了Wnt/β-catenin信号传递,心脏结构/功能,纤维化,炎症和纤维细胞激活.
主要成果:
- 在接受Ang II注射的小鼠中,LF3治疗显著改善了心脏功能和减弱了心室扩张.
- LF3减少了心肌纤维化和CD45+炎症细胞透.
- 在体外,LF3抑制了Ang II诱导的纤维细胞增殖,分化,迁移和原合成.
结论:
- 通过LF3对β-catenin/TCF4信号的药理学干扰是一种可行的策略.
- 在缓解Ang II诱导的心脏纤维化和功能障碍方面,LF3显示出有前途.
- LF3代表了与纤维化相关的心力衰竭的潜在治疗剂.
更多相关视频
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
7.8K
07:10Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts
Published on: May 16, 2021
5.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:30Heart Failure V: Medical Management
453
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
453
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:14Myocarditis III: Medical Management
286
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
286
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
602
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
602